+ Watch IMGN
on My Watchlist
The Company develops antibody-based anticancer therapeutics.
Been watching for a while and like the potential possibilities. Gambling on IMGN
Feels strange to red-thumb IMGN after so many years of owning it. But now they depend more on their internal pipeline development to justify their valuation, and certainly are not very good at it.
There's no question that the approval of T-DM1 for metastatic breast cancer is a great accomplishment for ImmunoGen. Where the company has fallen short is in the deal they made with Roche, in which their royalties will be only 3% of revenues up to 700M and then 5% after that. T-DM1 may become a multibillion dollar drug eventually but revenues will have to be 2.3 billion per year before ImmunoGen sees 100M of it. That potential and some phase I candidates don't justify a billion dollar enterprise value in my mind. ImmunoGen seems ripe for a pullback to levels closer to 12 seen at the beginning of 2013.
The technology is bearing fruit and could be applied to multiple cancers.
Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.
Value at this price.
CEO just bought 180,000 call options with a strike price at $15.83
Undervalued comparing with SGEN
I like their pipeline, there's no specific catalyst, that I'm aware of to pick this baby now. Perhaps in 5 years this will be more than a multibagger.I like the chances with this one.
just watching it go down. Will buy around 8$
It only take 1 good drug
This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.
Good approach to cancer therapy. A step away from traditional chemotherapy. Any breakthrough in adenocarcinoma tumor therapy will lead to application for prostate carcinoma. We have not had any real therapeutic breakthrough in a long time. The tools are now in the workshop!
Phase 2 clinical trials of cancer drug were characterized as striking, CEO claims Phase three trials may be done by 2014. I just like all the news so I will take a flyer...
Strong believe in lead drug
Confidence in receipt of FDA approval
I want my personal $ dedicated to this cause. I would root for any small bio co with the potential to make a significant difference in breast cancer treatment.
buy... hold... 2013.................
Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has failed other treatments.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions